Acetylcysteine effervescent tablets (DrugBank: Acetylcysteine)
11 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
34 | Neurofibromatosis | 0 |
84 | Sarcoidosis | 0 |
85 | Idiopathic interstitial pneumonia | 1 |
88 | Chronic thromboembolic pulmonary hypertension | 0 |
90 | Retinitis pigmentosa | 0 |
254 | Porphyria | 0 |
296 | Biliary atresia | 0 |
310 | Congenital anomalies syndrome | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04312594 (ClinicalTrials.gov) | August 13, 2020 | 27/2/2020 | Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis | A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Trial of Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets;Drug: Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets;Drug: Placebo oral tablet and Acetylcysteine Effervescent Tablets | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NULL | Recruiting | 50 Years | N/A | All | 90 | Phase 2 | China |